InvestmentUpdated on 14 July 2025
HOIST Corp. Ltd. undergoing Series B financing round
About
HOIST Corp. Ltd., established in 2019 in Osaka, Japan, is a clinical-stage biotechnology company founded on discoveries from The University of Osaka.
HOIST's lead program is HM-001, currently in a Phase I/IIa clinical study for bladder cancer. Additionally, HOIST Corp. is developing an inhibitor targeting ALKBH3, an epitranscriptomics drug target for pancreatic cancer.
HOIST Corp.’s key advantage lies in our Patient Derived Cells (PDC)/Patient Derived Xenografts (PDX) technology. By utilizing patient-derived cancer cells, PDC/PDX technology offers a superior model for mimicking the characteristics of cancer within the body. This makes it an excellent tool for testing lead compounds before initiating first-in-human studies.
HOIST Corp. is currently in the process of a Series B financing round. The raised capital will be allocated to further characterize HM-001 and optimize the development lead for our ALKBH3 inhibitor.
HOIST Corp. is currently preparing for a potential IPO.
We look forward to discussing investment opportunities with you at the conference.
Organisation
Similar opportunities
Project cooperation
SSO-001 for Osteoarthritis (OA)
- Research
- Execution
- Technical
- Financing
- Sales/Distribution